Originally published August 8.
NEW YORK (GenomeWeb) – Clovis Oncology this week reported that the company had incurred a net loss for the second quarter of $34.8 million, compared to $19.3 million in the second quarter of 2013.
A team led by researchers at the University of Copenhagen has completed a proteome-wide analysis of protein-polyADP-ribosylation, or PARylation, a post-translational modification thought to play a key role in DNA damage repair.
Clovis Oncology has decided to halt development of its investigational agent CO-101 as an alternative for pancreatic cancer patients who are poor responders to the standard chemotherapy agent gemcitabine after a clinical trial failed to show any improvement in survival time in a
Drug developer Clovis Oncology is planning to report data from a clinical trial later this year that may yield a new treatment option for pancreatic cancer patients who are poor responders to gemcitabine.